Hey there, bargain hunter.
Eli Lilly stock hit an all-time closing high of $1,229.93 on June 29, 2026. It is currently trading around $1,212. The 52-week low was $623.78. So yes, this stock has roughly doubled in a year. And no, the story is not over.
Three things happened in roughly the same eight-week window that could structurally reshape Lilly’s revenue trajectory for years.
First, the Q1 Numbers
Revenue came in at $19.8 billion, up 56% year-over-year. Volume climbed 65%. The company raised full-year 2026 revenue guidance from $80 to $83 billion all the way up to $82 to $85 billion. Mounjaro generated $8.7 billion in Q1 alone. Zepbound added $4.1 billion. Together, the two drugs brought in over $12.8 billion in a single quarter.
That is not a pharma number. That is a tech platform number in pharmaceutical clothing.
Second, Medicare Just Changed the Access Equation
As of July 1, 2026, the Medicare GLP-1 Bridge program went live. For the first time in the program’s history, Medicare is covering certain GLP-1 drugs for weight management through this temporary demonstration. Eligible Part D beneficiaries can access covered GLP-1 drugs for a $50 per month copayment. The program runs through December 31, 2027.
Lilly CEO Dave Ricks has said this could unlock access for millions of Medicare beneficiaries. That is a demand pool that has not appeared in any prescription data yet. The bottleneck was always access and cost. That bottleneck just moved.
Third, and This Is the Part the Market Is Not Fully Pricing: Retatrutide
On May 21, 2026, Lilly announced Phase 3 TRIUMPH-1 results for retatrutide, its next-generation triple agonist. The headline: 28.3% average body weight loss over 80 weeks at the 12 mg dose. That is roughly 70 pounds. At 104 weeks, participants with a baseline BMI of 35 or higher achieved up to 30.3% average weight loss, equivalent to about 85 pounds. Bariatric surgery typically produces 25 to 35% weight loss.
Retatrutide is not approved. It is not generating revenue. But the efficacy data just set a new bar for the entire category. Additional Phase 3 readouts from the TRIUMPH program are expected across 2026.
If even half of those deliver, Lilly has a third major GLP-1 product in the pipeline on top of two drugs that are already compounding at 100% year-over-year growth rates.
The Tensions Worth Knowing
Pricing pressure is real and is not going away. Lilly has highlighted that lower realized prices were a headwind in Q1. Realized pricing fell roughly 13% overall in Q1 and 25% outside the U.S. That is a material headwind, and it is one reason the stock can lag the business at times even as revenue accelerates.
Foundayo, Lilly’s oral GLP-1 pill, launched into a tough competitive spot. In its second week on pharmacy shelves, it generated around 3,707 prescriptions. Novo Nordisk’s oral Wegovy hit 18,410 in its first full week after launch. That gap weighed on sentiment and hit the stock.
Here’s where it gets interesting: Foundayo’s early prescription data predates Medicare Bridge coverage. The real demand test for the pill started July 1, not in April. That prescription data does not exist yet.
Valuation Check
At $1,212 per share, Lilly trades at roughly the low-30s times forward earnings (depending on the estimate set used). Market cap sits at approximately $1.14 trillion. That is a big number to grow into, but with a deep late-stage pipeline and a GLP-1 franchise that some analysts expect to become a very large global market over the next decade, the math is not obviously broken.
2026 EPS estimates have moved meaningfully higher in recent months. 2027 estimates have also moved higher over the same period. Estimates are moving in the right direction at the same time the stock is near its highs. That combination is either a sign of strength or a warning about expectations. Depends on your priors.
What I Am Watching
The next 60 days are the real data window. Foundayo’s weekly prescription trends under Medicare Bridge coverage will show whether oral GLP-1s can compete at scale or whether Wegovy built the habit first. Watch for Q2 earnings in late July or early August, where those script numbers will be the first number on every analyst’s list.
Any additional TRIUMPH retatrutide readouts are free options on top of an already compounding business. And the China situation deserves a watch too. Reports emerged in late June of GLP-1 copycat and generic activity proliferating in China, which can whipsaw sentiment even when the longer-term impact is hard to size.
Lilly is not a bargain in the traditional sense. It is near an all-time high, carries a premium multiple, and faces pricing pressure on its two most important products. But the Medicare demand unlock is new, retatrutide data is new, and the oral pill still has a full commercial ramp ahead of it. The growth wave the market has been pricing in may actually be smaller than what is coming.
